Medexus Pharmaceuticals (TSX:MDP) EV-to-EBIT : 8.23 (As of May. 22, 2025)

Medexus Pharmaceuticals EV-to-EBIT Chart

Medexus Pharmaceuticals Annual Data
	Trend	Mar15	Mar16	Mar17	Mar18	Mar19	Mar20	Mar21	Mar22	Mar23	Mar24
EV-to-EBIT		Get a 7-Day Free Trial					44.95	-6.76	11.23	9.41	5.47

Medexus Pharmaceuticals Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
EV-to-EBIT	Get a 7-Day Free Trial															6.40	5.47	5.84	7.94	8.16

Competitive Comparison of Medexus Pharmaceuticals's EV-to-EBIT

For the Drug Manufacturers - Specialty & Generic subindustry, Medexus Pharmaceuticals's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Medexus Pharmaceuticals's EV-to-EBIT Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Medexus Pharmaceuticals's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Medexus Pharmaceuticals's EV-to-EBIT falls into.

Medexus Pharmaceuticals EV-to-EBIT Calculation

Medexus Pharmaceuticals's EV-to-EBIT for today is calculated as:

Medexus Pharmaceuticals's current Enterprise Value is C$131.5 Mil.
Medexus Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was C$16.0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Medexus Pharmaceuticals  (TSX:MDP) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Medexus Pharmaceuticals's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2024 is calculated as:

Medexus Pharmaceuticals's Enterprise Value for the quarter that ended in Dec. 2024 was C$130.3 Mil.
Medexus Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was C$16.0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Medexus Pharmaceuticals EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Medexus Pharmaceuticals's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Medexus Pharmaceuticals Business Description